このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

USANA Health Sciences 将来の成長

Future 基準チェック /06

USANA Health Sciencesの収益は年間0.3%で減少すると予測されていますが、年間収益は年間1%で増加すると予想されています。EPS は年間0.6%で減少すると予想されています。

主要情報

-0.3%

収益成長率

-0.6%

EPS成長率

Personal Products 収益成長	23.1%
収益成長率	1.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Jun 2024

今後の成長に関する最新情報

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Recent updates

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

May 29

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Jul 27

USANA Earnings Preview: From China's Challenge To India's Promise

Jul 21

USANA Health Sciences says Brown will transition to CEO in July 2023

Feb 13

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

Feb 02

USANA Health Sciences down 17% after revising 2022 outlook below consensus estimates

Oct 25

Here's What To Make Of USANA Health Sciences' (NYSE:USNA) Decelerating Rates Of Return

Oct 18

Are Investors Undervaluing USANA Health Sciences, Inc. (NYSE:USNA) By 26%?

Jul 22

Returns On Capital At USANA Health Sciences (NYSE:USNA) Have Stalled

Jul 07

Is USANA Health Sciences (NYSE:USNA) Using Too Much Debt?

Jun 14

Is USANA Health Sciences, Inc. (NYSE:USNA) Potentially Undervalued?

May 31

USANA: Soft Quarter, Bottomed Out Stock, 9.8x Ex-Cash P/E, 65% Upside

Apr 28

Capital Investments At USANA Health Sciences (NYSE:USNA) Point To A Promising Future

Mar 05

USANA: 15x P/E, 14% Net Cash, Stock Repurchases

Feb 17

業績と収益の成長予測

NYSE:USNA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	914	61	69	85	2
12/31/2024	884	54	61	78	2
3/30/2024	900	62	60	75	N/A
12/30/2023	921	64	56	71	N/A
9/30/2023	928	60	75	85	N/A
7/1/2023	948	63	79	92	N/A
4/1/2023	974	65	86	97	N/A
12/31/2022	999	69	94	104	N/A
10/1/2022	1,038	77	78	88	N/A
7/2/2022	1,079	89	84	97	N/A
4/2/2022	1,151	108	108	121	N/A
1/1/2022	1,186	117	108	121	N/A
10/2/2021	1,230	136	133	144	N/A
7/3/2021	1,254	139	148	156	N/A
4/3/2021	1,176	129	140	149	N/A
1/2/2021	1,135	125	145	160	N/A
9/26/2020	1,095	116	149	168	N/A
6/27/2020	1,058	110	149	169	N/A
3/28/2020	1,055	103	131	152	N/A
12/28/2019	1,061	101	110	127	N/A
9/28/2019	1,089	102	97	111	N/A
6/29/2019	1,125	109	104	116	N/A
3/30/2019	1,170	121	127	138	N/A
12/29/2018	1,189	126	141	152	N/A
9/29/2018	1,163	88	154	167	N/A
6/30/2018	1,128	81	112	125	N/A
3/31/2018	1,084	70	129	141	N/A
12/30/2017	1,047	63	N/A	124	N/A
9/30/2017	1,027	90	N/A	124	N/A
7/1/2017	1,020	97	N/A	145	N/A
4/1/2017	1,021	99	N/A	125	N/A
12/31/2016	1,006	100	N/A	137	N/A
10/1/2016	986	102	N/A	119	N/A
7/2/2016	965	98	N/A	113	N/A
4/2/2016	940	97	N/A	101	N/A
1/2/2016	918	95	N/A	111	N/A
10/3/2015	914	92	N/A	112	N/A
7/4/2015	872	86	N/A	120	N/A
4/4/2015	827	80	N/A	126	N/A
1/3/2015	790	77	N/A	105	N/A
9/27/2014	749	76	N/A	102	N/A
6/28/2014	731	73	N/A	83	N/A
3/29/2014	731	78	N/A	81	N/A
12/28/2013	718	79	N/A	99	N/A
9/28/2013	700	77	N/A	94	N/A
6/29/2013	692	78	N/A	96	N/A

アナリストによる今後の成長予測

収入対貯蓄率: USNAの収益は今後 3 年間で減少すると予測されています (年間-0.3% )。

収益対市場: USNAの収益は今後 3 年間で減少すると予測されています (年間-0.3% )。

高成長収益: USNAの収益は今後 3 年間で減少すると予測されています。

収益対市場: USNAの収益 ( 1% ) US市場 ( 8.4% ) よりも低い成長が予測されています。

高い収益成長: USNAの収益 ( 1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: USNAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

USANA Health Sciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target decreased by 17% to US$56.50

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target increased by 8.8% to US$74.00

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

Recent updates

Founder & Chairman Emeritus recently sold US$180k worth of stock

Founder & Chairman Emeritus notifies of intention to sell stock

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

Chief People Officer recently sold US$132k worth of stock

Now 22% undervalued

Chief Financial Officer recently sold US$233k worth of stock

Insider notifies of intention to sell stock

Insider recently sold US$179k worth of stock

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

First quarter 2024 earnings: EPS exceeds analyst expectations

Is Now The Time To Look At Buying USANA Health Sciences, Inc. (NYSE:USNA)?

USANA Health Sciences, Inc. to Report Q1, 2024 Results on Apr 30, 2024

USANA Health Sciences, Inc.'s (NYSE:USNA) Prospects Need A Boost To Lift Shares

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

New minor risk - Insider selling

Chief Legal Officer recently sold US$232k worth of stock

Price target decreased by 17% to US$56.50

Chief Financial Officer exercised options and sold US$161k worth of stock

New major risk - Revenue and earnings growth

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

Full year 2023 earnings: EPS exceeds analyst expectations

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Is It Too Late To Consider Buying USANA Health Sciences, Inc. (NYSE:USNA)?

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.8% to US$74.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

USANA: New Digital Tools And Solid Balance Sheet Imply Undervaluation

USANA Health Sciences, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Are Investors Undervaluing USANA Health Sciences, Inc. (NYSE:USNA) By 22%?

Now 21% undervalued after recent price drop

Chief People Officer recently sold US$239k worth of stock

Chief People Officer notifies of intention to sell stock

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

USANA Earnings Preview: From China's Challenge To India's Promise

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Price target increased by 22% to US$64.00

Insufficient new directors

Chief Sales Officer notifies of intention to sell stock

Insider recently sold US$811k worth of stock

Independent Director recently sold US$165k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman of the Board & CEO recently sold US$319k worth of stock

Chairman of the Board & CEO notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023

USANA Health Sciences says Brown will transition to CEO in July 2023

Insider recently sold US$116k worth of stock

Chairman of the Board & CEO exercised options and sold US$179k worth of stock

Usana Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2023

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

USANA Health Sciences, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

USANA Health Sciences, Inc. (NYSE:USNA) acquired Rise Bar and Oola Global, LLC.

Price target decreased to US$49.00

Consensus EPS estimates fall by 17%

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

USANA Health Sciences down 17% after revising 2022 outlook below consensus estimates

Here's What To Make Of USANA Health Sciences' (NYSE:USNA) Decelerating Rates Of Return

USANA Health Sciences, Inc. to Report Q3, 2022 Results on Oct 25, 2022

Now 21% undervalued after recent price drop

Chief People Officer recently sold US$352k worth of stock

Price target decreased to US$55.00